Recent studies provide convincing evidence that a DLBCL population characterized by the coexpression of MYC and BCL2 proteins by IHC has a poor prognosis with standard rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) immunochemotherapy [12]–[14]. Here, BCL2 is linked to diffuse large B-cell lymphoma.